Description
TSA-CTL (Tumor-Specific Antigen Cytotoxic T Lymphocytes) refers to an experimental adoptive cell therapy approach in which cytotoxic T lymphocytes are expanded and activated ex vivo against tumor-specific antigens before being infused back into the patient. This approach has been explored in various solid tumors including colorectal cancer, primarily in early-phase clinical trials. It is not an established standard-of-care treatment for CRC and remains investigational, with limited published data on efficacy in this setting.
Mechanism of Action
TSA-CTLs work by harnessing the patient's own (or donor) cytotoxic T cells that are specifically primed to recognize tumor-associated or tumor-specific antigens expressed on cancer cells. Once infused, these activated T lymphocytes seek out and kill cancer cells through direct cytotoxic mechanisms including perforin/granzyme-mediated cell lysis.
Side Effects
Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.
Clinical Trials
Quick Info
| Category | Other Medications |
 Status | Experimental |
 EMA Status | Experimental |
 Spain Access | Not available |
| Administration | IV |
| Clinical Trials | 1 |
Related Medications
Medical Disclaimer
This information is for educational purposes only and should not replace professional medical advice. Always consult your healthcare team before making treatment decisions.